1620136-60-8

Upstream product

• 1389310-06-8 (S)-2-(trifluoromethyl)pyrrolidine hydrochloride 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 119580-41-5 (S)-(+)-2-(trifluoromethyl)pyrrolidine 

Downstream Products

• 1620136-62-0 (S)-6-(2-(2-(trifluoromethyl)pyrrolidin-1-yl)pyrimidin-5-yl)pyridine-2-amine 
• 1620136-70-0 (S)-6-(2-(2-(trifluoromethyl)pyrrolidin-1-yl)pyrimidin-5-yl)pyrazin-2-amine 
• 1620136-61-9 (S)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(2-(trifluoromethyl)pyrrolidin-1-yl)pyrimidine 

Relevant academic research and scientific papers

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.